Conference bulletins

We sent out four free email summary bulletins to subscribers, presenting a round-up of news from CROI 2013, with links to full news reports, abstracts and webcasts where available.

The bulletins are available in English, French, Spanish, Portuguese, Italian and Russian.

The complete set of conference bulletins are available below to read online or download as PDFs.

We report on latest news all year round! Sign up to one (or more!) of our regular bulletins here, and you will automatically receive daily bulletins from future conferences. You can also sign up for conference coverage only on the right-hand side of this page. Please bear in mind that we usually only produce daily translated coverage for two conferences each year.

Bulletins

English

  • Wednesday 13th March 2013 (HTML | PDF)
  • Thursday 7th March 2013 (HTML | PDF)
  • Wednesday 6th March 2013 (HTML | PDF)
  • Tuesday 5th March 2013 (HTML | PDF)

French

Portuguese

  • Quarta-feira, 13 de março de 2013 (HTML | PDF)
  • Quinta-feira 7 de março de 2013 (HTML | PDF)
  • Quarta-feira, 6 de março de 2013 (HTML | PDF)
  • Terça-feira, 5 de março de 2013 (HTML | PDF)

Spanish

  • Miércoles, 13 de marzo de 2013 (HTML | PDF)
  • Jueves, 7 de marzo de 2013 (HTML | PDF)
  • Miércoles, 6 de marzo de 2013 (HTML | PDF)
  • Martes, 5 de marzo de 2013 (HTML | PDF)

Italian

  • Mercoledì 13 marzo 2013 (HTML | PDF)
  • Giovedì 7 marzo 2013 (HTML | PDF)
  • Mercoledì 6 marzo 2013 (HTML | PDF)
  • Martedì 5 marzo 2013 (HTML | PDF)

Russian

  • Среда, 13-ое марта 2013 (HTML | PDF)
  • Четверг, 7-ое марта 2013 (HTML | PDF)
  • Среда, 6-ое марта 2013 (HTML | PDF)
  • Вторник, 5-ое марта 2013 (HTML | PDF)

Subscribe now

Sign up for our conference email bulletins below

NAM is partnering with gTt (Barcelona), GAT (Lisbon) and LILA (Como) to deliver the CROI 2013 bulletins, which have also been made possible thanks to support from Bristol-Myers Squibb. NAM’s wider conference news reporting services have been supported by Abbott, Boehringer Ingelheim, Janssen, Roche and ViiV Healthcare. The funders have no editorial control over the content of the materials.